一家机构10年间内肉毒杆菌毒素A治疗内收性痉挛性发声障碍的剂量趋势
Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years.
作者信息
Bradley Joseph P, Barrow Emily M, Hapner Edie R, Klein Adam M, Johns Michael M
机构信息
Department of Otolaryngology-Head & Neck Surgery, Washington University in St. Louis School of Medicine, St. Louis, Missouri.
Department of Otolaryngology-Head & Neck Surgery, Emory Voice Center, Atlanta, Georgia.
出版信息
J Voice. 2017 May;31(3):363-365. doi: 10.1016/j.jvoice.2016.09.022. Epub 2016 Nov 10.
OBJECTIVES
This study aimed to identify the changes in dosing of botulinum toxin-A for adductor spasmodic dysphonia (ADSD) over a prolonged period.
STUDY DESIGN
This is a retrospective chart review.
METHODS
One hundred thirteen subjects treated for ADSD from 2003 to 2013 were identified from a clinical database. Subject age, gender, and total injection dose amount were all recorded for all subjects who had at least 10 injections.
RESULTS
Fifty-four subjects met criteria for inclusion. There were no age or gender differences in the starting dose for subjects. Dosing decreased significantly compared with the second dose (5.05 ± 1.623 Units), by the sixth dose (4.26 ± 1.698 Units), and continued through the 10th dose (4.08 ± 2.019 Units) (P < 0.005 for all).
CONCLUSIONS
Botulinum toxin-A dosing for ADSD decreases consistently over subsequent injections after the initial two dose titrations.
目的
本研究旨在确定长期内肉毒杆菌毒素A用于治疗内收肌痉挛性发音障碍（ADSD）时剂量的变化。
研究设计
这是一项回顾性病历审查。
方法
从临床数据库中识别出2003年至2013年期间接受ADSD治疗的113名受试者。记录了所有至少接受10次注射的受试者的年龄、性别和总注射剂量。
结果
54名受试者符合纳入标准。受试者的起始剂量在年龄或性别上无差异。与第二剂（5.05±1.623单位）相比，第六剂（4.26±1.698单位）时剂量显著降低，并持续到第十剂（4.08±2.019单位）（所有P<0.005）。
结论
在最初两次剂量滴定后，后续注射中用于ADSD的肉毒杆菌毒素A剂量持续下降。
Zotero 插件